Mouse anti Human Cytochrome p450 26A1
| Code | Size | Price |
|---|
| EXA-X2049M | 200 ug | £316.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: F27 P6 A1
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Shipping:
Ship at ambient temperature freeze upon arrival
Storage:
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles
Further Information
Applications Description:
Antibody can be used for Western blotting (1-2 ?g/ml) and immunohistochemistry on formalin-fixed, paraffin-embedded tissues (1-5 ?g/ml). Optimal concentration should be evaluated by serial dilutions.
Background:
The cytochrome P450 proteins (CYPs) are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. P450 enzymes are classified into subfamilies based on their sequence similarities. CYP26A1, also referred to as retinoic acid-4-hydroxylase, is a major retinoic acid catabolic enzyme. CYP26A1 plays an important role in protecting tailbud tissues from inappropriate exposure to retinoic acid. CYP26A1 transcription is epigenetically regulated by nuclear retinoic acid receptors 2. Mutations in the gene encoding for CYP26A1 are associated with caudal agenesis and spina bifida, imperforate anus, agenesis of the caudal portions of the digestive and urogenital tracts, and malformed lumbosacral skeletal elements. CYP26A1 is upregulated in adenomatous polyposis coli mouse adenomas, human FAP adenomas, human sporadic colon carcinomas, and in the intestine of adenomatous polyposis coli(mcr) mutant zebrafish embryos.
Caution:
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
Concentration:
See vial for concentration
Field of Interest:
Cell Cycle
Formulation:
Provided as solution in phosphate buffered saline with 0.08% sodium azide
Functional Analysis:
Western Blotting
Immunogen:
Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with a synthetic peptide derived from the C-terminus of the human CYP450 26A1 protein and mouse myeloma Ag8563 cells.
Positive Control:
Liposarcoma cells
Product Form:
Unconjugated
Product Stability:
Products are stable for one year from purchase when stored properly
Purification Method:
Protein A/G Chromatography
Synonyms:
CYP450 26 (EC 1.14.-.-); Retinoic acid-metabolizing cytochrome; P450 retinoic acid-inactivating 1; P450RAI; hP450RAI; Retinoic acid 4-hydroxylase
UniProt:
O43174 (Human)
References
1. Kumarakasingham, M., et al. (2005). Cytochrome p450 profile of colorectal cancer: Identification of markers of prognosis. Clin. Cancer Res. 11(10);3758-3765.
2. Sakai, Y., et al. (2004). CYP26A1 and CYP26C1 cooperate in degrading retinoic acid within the equatorial retina during later eye development. 276(1);143-157
3. Osanai, M. and Petkovich, M. (2005). Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. 67(5);1808-1817
2. Sakai, Y., et al. (2004). CYP26A1 and CYP26C1 cooperate in degrading retinoic acid within the equatorial retina during later eye development. 276(1);143-157
3. Osanai, M. and Petkovich, M. (2005). Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. 67(5);1808-1817